VitaNova Life Sciences (VNOV) Equity Ratio (2017 - 2026)

VitaNova Life Sciences has reported Equity Ratio for 9 years, with the latest figure at 0.8 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio fell 4.41% year-over-year to 0.8; the trailing twelve-month figure through Jan 2026 stood at 0.8 (down 4.41% YoY), and the FY2025 full-year result was 0.85, down 4.44% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.8, down from 0.81 in the prior quarter.
• The five-year high for Equity Ratio was 0.9 in Q1 2024, with the low at 6.78 in Q2 2023.
• Historically, Equity Ratio has averaged 0.52 across 5 years, with a median of 0.81 in 2025.
• Annual changes were most pronounced in 2023 — Equity Ratio slumped 2474.83% — and 2024, when it surged 118.14%.
• VitaNova Life Sciences' Equity Ratio stood at 0.86 in 2022, then plunged by 689.16% to 6.78 in 2023, then jumped by 112.12% to 0.82 in 2024, then decreased by 1.17% to 0.81 in 2025, then slipped by 1.3% to 0.8 in 2026.
• The last three Equity Ratio figures came in at 0.8 (Q1 2026), 0.81 (Q4 2025), and 0.83 (Q3 2025), per Business Quant data.